Momenta Pharmaceuticals Announces Date Of First Quarter 2013 Financial Results Conference Call And Webcast

CAMBRIDGE, Mass., April 9, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2013 before the U.S. financial markets open on Tuesday, April 30, 2013.

Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 34140526. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel drugs.

To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
CONTACT: Lora Pike         Momenta Pharmaceuticals, Inc.         lpike@momentapharma.com

If you liked this article you might like

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

The Stock Market Is on Autopilot

The Stock Market Is on Autopilot

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers